Cambridge, United Kingdom

Mark David Rackham

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 7.0

ph-index = 8

Forward Citations = 114(Granted Patents)


Location History:

  • Welwyn Garden, GB (2018)
  • Welwyn Garden City, GB (2017 - 2019)
  • Cambridge, GB (2019 - 2022)

Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Mark David Rackham: Innovator in Muscarinic Agonists

Introduction

Mark David Rackham is a distinguished inventor based in Cambridge, GB, with an impressive portfolio of 8 patents to his name. His work primarily revolves around the development of compounds that target muscarinic receptors, which are crucial in the treatment of various diseases. Rackham’s innovations contribute significantly to the pharmaceutical field, where they hold promise for improving therapeutic outcomes.

Latest Patents

Among his latest patents, Rackham has focused on muscarinic agonists. One notable invention relates to compounds that act as agonists of the muscarinic M receptor, aimed at treating diseases linked to muscarinic M/M receptor pathways. This patent also highlights pharmaceutical compositions containing these compounds and discusses their therapeutic applications.

Additionally, Rackham has developed bicyclic AZA compounds specifically targeting muscarinic M1 and M4 receptors. These compounds are designed to provide therapeutic options for diseases associated with M1/M4 receptor-mediated pathways. The patent includes various formulations and details their potential uses in medicine.

Career Highlights

Mark David Rackham is associated with Heptares Therapeutics Limited, a company renowned for its innovative approach in the development of new therapies. His expertise in pharmacology and chemistry has propelled advancements in drug discovery, making him a key figure in the realm of biopharmaceutical research.

Collaborations

Throughout his career, Rackham has collaborated with notable colleagues such as Giles Albert Brown and Miles Stuart Congreve. Their combined efforts have fostered a supportive environment for innovation, leading to the successful development of novel therapeutics focusing on muscarinic receptors.

Conclusion

Mark David Rackham’s contributions to the field of pharmaceuticals, especially his advancements in muscarinic agonists, underscore the importance of innovation in healthcare. His ongoing research efforts continue to inspire new possibilities for treating complex diseases, marking him as a significant inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…